Iwanari O, Miyako J, Ryuko K, Date Y, Moriyama M, Moriyama M, Kijima S, Yoshino N, Kitao M
Nihon Gan Chiryo Gakkai Shi. 1989 Oct 20;24(10):2355-61.
The immunological effect has been studied of the non-specific immunopotentiator sizofiran (SPG) on patients with advanced uterine cervical cancer treated with radiation. Ten cases (study group: SPG group) were administered weekly 40 mg of SPG throughout the course of radiation and two weekly 40 mg during 12 months after radiotherapy. Nineteen cases (control group) were treated with irradiation alone. The lymphocyte count, the PHA index and the ratio of CD4 cells/CD8 cells were significantly reduced by radiotherapy, being observed the most remarkable decrease at post-radiotherapy. But in SPG group, these decreasing values were significantly smaller than in control group and the values showed a more progressive rise during the 12 month respectively. There was no significant difference in peripheral T lymphocyte; CD3, CD4, CD8. The NK cytotoxic activity showed a progressive rise during the 12 month period following a minimal change after radiotherapy. These results suggest that the SPG have some enhancing effect on the function of the lymphocytes.
已对非特异性免疫增强剂裂褶多糖（SPG）对接受放疗的晚期子宫颈癌患者的免疫作用进行了研究。10例患者（研究组：SPG组）在放疗全过程中每周给予40mg SPG，并在放疗后12个月内每周两次给予40mg。19例患者（对照组）仅接受放疗。放疗使淋巴细胞计数、PHA指数及CD4细胞/CD8细胞比值显著降低，放疗后下降最为明显。但在SPG组，这些下降值明显小于对照组，且在12个月内分别呈更明显的上升趋势。外周血T淋巴细胞；CD3、CD4、CD8无显著差异。NK细胞毒性活性在放疗后有微小变化，随后在12个月内呈逐渐上升趋势。这些结果表明，SPG对淋巴细胞功能有一定的增强作用。
